Dashboard
1
Poor Management Efficiency with a low ROCE of 0.64%
- The company has been able to generate a Return on Capital Employed (avg) of 0.64% signifying low profitability per unit of total capital (equity and debt)
2
Flat results in Mar 25
3
With ROE of 3.67%, it has a attractive valuation with a 1.36 Price to Book Value
4
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
CNY 2,369 Million (Small Cap)
37.00
NA
0.47%
-0.17
4.93%
1.50
Revenue and Profits:
Net Sales:
143 Million
(Quarterly Results - Sep 2025)
Net Profit:
28 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
7.1%
0%
7.1%
6 Months
5.69%
0%
5.69%
1 Year
24.84%
0%
24.84%
2 Years
4.58%
0%
4.58%
3 Years
2.57%
0%
2.57%
4 Years
6.39%
0%
6.39%
5 Years
82.0%
0%
82.0%
Ginwa Enterprise (Group) Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-2.58%
EBIT Growth (5y)
20.24%
EBIT to Interest (avg)
1.03
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.07
Sales to Capital Employed (avg)
0.34
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
14.18%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0.64%
ROE (avg)
1.63%
Valuation key factors
Factor
Value
P/E Ratio
37
Industry P/E
Price to Book Value
1.36
EV to EBIT
760.89
EV to EBITDA
76.90
EV to Capital Employed
1.39
EV to Sales
3.51
PEG Ratio
0.01
Dividend Yield
0.53%
ROCE (Latest)
0.18%
ROE (Latest)
3.67%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
142.60
132.40
7.70%
Operating Profit (PBDIT) excl Other Income
16.70
0.30
5,466.67%
Interest
1.30
1.50
-13.33%
Exceptional Items
-1.80
0.00
Consolidate Net Profit
28.10
5.00
462.00%
Operating Profit Margin (Excl OI)
117.00%
-47.90%
16.49%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 7.70% vs 24.55% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 462.00% vs 316.67% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
580.10
557.10
4.13%
Operating Profit (PBDIT) excl Other Income
30.30
43.90
-30.98%
Interest
6.30
4.50
40.00%
Exceptional Items
-7.60
-28.10
72.95%
Consolidate Net Profit
73.60
-42.90
271.56%
Operating Profit Margin (Excl OI)
12.00%
3.00%
0.90%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 4.13% vs -2.72% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 271.56% vs -228.06% in Dec 2023
About Ginwa Enterprise (Group) Inc. 
Ginwa Enterprise (Group) Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






